Search Results - "Wilding, J. P. H"

The importance of free fatty acids in the development of Type 2 diabetes by Wilding, J. P. H.

“…The recent increase in the prevalence of obesity has been associated with a coincident rise in the prevalence of Type 2 diabetes, whereas weight loss has been…”
Get full text

The importance of weight management in type 2 diabetes mellitus by Wilding, J P H

“…The obesity epidemic is driving the increased prevalence of type 2 diabetes mellitus (T2DM), and the vast majority of patients with T2DM are overweight or…”
Get more information

Neuropeptides and appetite control by Wilding, J. P. H.

“…Obesity is important in the aetiology of type 2 diabetes, and presents a major barrier to its successful prevention and management. Obesity develops when…”
Get full text

The four-variable modification of diet in renal disease formula underestimates glomerular filtration rate in obese type 2 diabetic individuals with chronic kidney disease by Nair, S., Mishra, V., Hayden, K., Lisboa, P. J. G., Pandya, B., Vinjamuri, S., Hardy, K. J., Wilding, J. P. H.

“…Aims/hypothesis GFR is commonly estimated using the four-variable Modification of Diet in Renal Disease (MDRD) formula and this forms the basis for…”
Get full text

Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition by Rajeev, S. P., Cuthbertson, D. J., Wilding, J. P. H.

“…Sodium‐glucose co‐transporter 2 (SGLT2) inhibitors are the latest addition to the class of oral glucose‐lowering drugs. They have been rapidly adopted into…”
Get full text

A parametric analysis of olanzapine-induced weight gain in female rats by COOPER, G. D, PICKAVANCE, L. C, WILDING, J. P. H, HALFORD, J. C. G, GOUDIE, A. J

“…Some novel antipsychotics, including olanzapine, induce weight gain and metabolic abnormalities, which represent the major adverse effects of these drugs…”
Get full text

Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study by Wilding, J. P. H., Ferrannini, E., Fonseca, V. A., Wilpshaar, W., Dhanjal, P., Houzer, A.

“…Aims Ipragliflozin is a novel, selective inhibitor of sodium glucose co‐transporter 2 (SGLT2 inhibitor) in clinical development for type 2 diabetes mellitus…”
Get full text

Impact of bariatric surgery on physical functioning in obese adults by Steele, T, Cuthbertson, D. J, Wilding, J. P. H

“…Obesity is associated with a profound impairment in the ability to perform the basic physical activities required for everyday function. This impacts on…”
Get full text

Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin by Wilding, J. P. H., Leonsson-Zachrisson, M., Wessman, C., Johnsson, E.

“…Aim To investigate the effect of glucokinase activator AZD1656 on glycated haemoglobin (HbA1c) as an add‐on to metformin in patients with type 2 diabetes…”
Get full text

Cardiovascular and metabolic effects of CPAP in obese males with OSA by Coughlin, S. R, Mawdsley, L, Mugarza, J. A, Wilding, J. P. H, Calverley, P. M. A

“…Obstructive sleep apnoea is associated with increased blood pressure and other features of the metabolic syndrome. The aim of the present study was to…”
Get full text

Ghrelin does not orchestrate the metabolic changes seen in fasting but has significant effects on lipid mobilisation and substrate utilisation by Huda, M S B, Dovey, T M, Wong, S P, English, P J, Halford, J C G, McCulloch, P, Cleator, J, Martin, B, Cashen, J, Hayden, K, Ghatei, M A, Bloom, S R, Wilding, J P H, Pinkney, J H

“…ObjectiveShort-term fasting is associated with increased GH pulsatility and mobilisation of fats, but underlying mechanisms are unclear. We studied ghrelin's…”
Get full text

Gut peptides and the regulation of appetite by Huda, M. S. B., Wilding, J. P. H., Pinkney, J. H.

“…Summary There is a growing worldwide epidemic of obesity. Obese people have a higher incidence of type 2 diabetes and cardiovascular disease, and hence present…”
Get full text

Metformin prolongs the postprandial fall in plasma ghrelin concentrations in type 2 diabetes by English, P. J., Ashcroft, A., Patterson, M., Dovey, T. M., Halford, J. C. G., Harrison, J., Eccleston, D., Bloom, S. R., Ghatei, M. A., Wilding, J. P. H.

“…Background Weight loss is difficult to achieve in type 2 diabetes and many therapies are associated with weight gain, an effect attenuated by metformin. We…”
Get full text

Effects of peripheral administration of synthetic human glucose-dependent insulinotropic peptide (GIP) on energy expenditure and subjective appetite sensations in healthy normal weight subjects and obese patients with type 2 diabetes by Daousi, C., Wilding, J. P. H., Aditya, S., Durham, B. H., Cleator, J., Pinkney, J. H., Ranganath, L. R.

“…Summary Background  Apart from their role in insulin secretion and glucose homeostasis, the incretin hormones glucagon‐like peptide‐1 (GLP‐1) and…”
Get full text

Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation by Bray, G.A, Kim, K.K, Wilding, J.P.H

“…Summary This paper considers the argument for obesity as a chronic relapsing disease process. Obesity is viewed from an epidemiological model, with an agent…”
Get full text

Plasma obestatin levels are lower in obese and post-gastrectomy subjects, but do not change in response to a meal by Huda, M S B, Durham, B H, Wong, S P, Deepak, D, Kerrigan, D, McCulloch, P, Ranganath, L, Pinkney, J, Wilding, J P H

“…Objective: To investigate a potential role for obestatin in humans by examining response to a fixed energy meal. Context: A new anorectic peptide hormone,…”
Get full text

Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years by Wilding, J. P. H., Woo, V., Rohwedder, K., Sugg, J., Parikh, S.

“…Aims Dapagliflozin, a selective inhibitor of sodium‐glucose cotransporter 2 (SGLT2), has been shown to improve glycaemic control, stabilize insulin dosing and…”
Get full text

Ghrelin inhibits autonomic function in healthy controls, but has no effect on obese and vagotomized subjects by Huda, M. S. B., Mani, H., Dovey, T., Halford, J. C. G., Boyland, E., Daousi, C., Wilding, J. P. H., Pinkney, J.

“…Summary Objective  Ghrelin inhibits sympathetic nervous system (SNS) activity in rodents. We studied the effect of ghrelin on healthy humans, in obesity and in…”
Get full text

Ghrelin restores 'lean-type' hunger and energy expenditure profiles in morbidly obese subjects but has no effect on postgastrectomy subjects by Huda, M.S.B, Dovey, T, Wong, S.P, English, P.J, Halford, J, Mcculloch, P, Cleator, J, Martin, B, Cashen, J, Hayden, K, Wilding, J.P.H, Pinkney, J

“…Objective: To examine the effects of ghrelin on appetite and energy expenditure in lean, obese and postgastrectomy subjects. Design: A randomized,…”
Get full text

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial by Wilding, J P H, Charpentier, G, Hollander, P, González-Gálvez, G, Mathieu, C, Vercruysse, F, Usiskin, K, Law, G, Black, S, Canovatchel, W, Meininger, G

“…Canagliflozin is a sodium glucose co-transporter 2 inhibitor developed for the treatment of type 2 diabetes mellitus (T2DM). This randomised, double-blind,…”
Get more information